Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis
NCT00244179Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2003
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of interferon gamma-1b and infliximab in reactive arthritis (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Change in intensity of pain and Change in function (WOMAC). Status: unknown.
02
Drugs
interferon gamma-1binfliximab
03
Conditions
reactive arthritis
Beyond the preview
Go deeper on NCT00244179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244179.